Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | GRM7 | Q14831 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL4230295 | 0.90 | TRPV1 (0.42) | ALDH1A1KDM4ETSHRGRM7MEN1 | |
| Trifluoroacetic Acid SCHEMBL4232671 | 0.90 | POLB (0.44) | ALDH1A1KDM4ETSHRGRM7MEN1 | |
| Trifluoroacetic Acid SCHEMBL4227076 | 0.80 | GRM7 (0.48) | ALDH1A1KDM4ETSHRGRM7MEN1 | |
| Trifluoroacetic Acid SCHEMBL4228572 | 0.78 | HTR2A (0.46) | — | |
| Trifluoroacetic Acid SCHEMBL4228571 | 0.78 | HTR2A (0.46) | — | |
| SCHEMBL4233612 | 0.72 | GRM7 (0.57) | ALDH1A1KDM4ETSHRGRM7MEN1 | |
| Trifluoroacetic Acid SCHEMBL4230514 | 0.71 | GRM7 (0.87) | ALDH1A1KDM4ETSHRGRM7MEN1 | |
| Trifluoroacetic Acid SCHEMBL4231735 | 0.71 | GRM7 (0.87) | ALDH1A1KDM4ETSHRGRM7MEN1 | |
| Trifluoroacetic Acid SCHEMBL4227823 | 0.71 | GRM7 (0.87) | ALDH1A1KDM4ETSHRGRM7MEN1 | |
| Trifluoroacetic Acid SCHEMBL4227404 | 0.70 | GRM7 (0.68) | ALDH1A1KDM4ETSHRGRM7MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2096104-A1 | Organic diamines as mGluR7 modulators | Novartis AG (CH) | 2009-09-02 | — | — | EP | disclosed |
| US-20080242698-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242698-A1 | Organic Compounds | AOC1, OTC, ODC1 | ALDH1A1 266/4885KDM4E 2294/4885TSHR 4417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.